195 related articles for article (PubMed ID: 27863408)
1. An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer.
Shahid M; Choi TG; Nguyen MN; Matondo A; Jo YH; Yoo JY; Nguyen NN; Yun HR; Kim J; Akter S; Kang I; Ha J; Maeng CH; Kim SY; Lee JS; Kim J; Kim SS
Oncotarget; 2016 Dec; 7(52):86561-86572. PubMed ID: 27863408
[TBL] [Abstract][Full Text] [Related]
2. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
Zhu CQ; Ding K; Strumpf D; Weir BA; Meyerson M; Pennell N; Thomas RK; Naoki K; Ladd-Acosta C; Liu N; Pintilie M; Der S; Seymour L; Jurisica I; Shepherd FA; Tsao MS
J Clin Oncol; 2010 Oct; 28(29):4417-24. PubMed ID: 20823422
[TBL] [Abstract][Full Text] [Related]
4. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
5. KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.
Nagy Á; Pongor LS; Szabó A; Santarpia M; Győrffy B
Int J Cancer; 2017 Feb; 140(4):930-937. PubMed ID: 27859136
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
Kim JH; Kim HS; Kim BJ
Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
[TBL] [Abstract][Full Text] [Related]
7. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
8. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.
Tang H; Xiao G; Behrens C; Schiller J; Allen J; Chow CW; Suraokar M; Corvalan A; Mao J; White MA; Wistuba II; Minna JD; Xie Y
Clin Cancer Res; 2013 Mar; 19(6):1577-86. PubMed ID: 23357979
[TBL] [Abstract][Full Text] [Related]
9. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
[TBL] [Abstract][Full Text] [Related]
10. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.
Zuo S; Wei M; Zhang H; Chen A; Wu J; Wei J; Dong J
J Transl Med; 2019 May; 17(1):152. PubMed ID: 31088477
[TBL] [Abstract][Full Text] [Related]
11. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.
Chen DT; Hsu YL; Fulp WJ; Coppola D; Haura EB; Yeatman TJ; Cress WD
J Natl Cancer Inst; 2011 Dec; 103(24):1859-70. PubMed ID: 22157961
[TBL] [Abstract][Full Text] [Related]
13. Molecular gene signature and prognosis of non-small cell lung cancer.
Huang P; Cheng CL; Chang YH; Liu CH; Hsu YC; Chen JS; Chang GC; Ho BC; Su KY; Chen HY; Yu SL
Oncotarget; 2016 Aug; 7(32):51898-51907. PubMed ID: 27437769
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.
Ahrendt SA; Hu Y; Buta M; McDermott MP; Benoit N; Yang SC; Wu L; Sidransky D
J Natl Cancer Inst; 2003 Jul; 95(13):961-70. PubMed ID: 12837832
[TBL] [Abstract][Full Text] [Related]
15. A novel 12-gene signature as independent prognostic model in stage IA and IB lung squamous cell carcinoma patients.
Wang K; Li Y; Wang J; Chen R; Li J
Clin Transl Oncol; 2021 Nov; 23(11):2368-2381. PubMed ID: 34028782
[TBL] [Abstract][Full Text] [Related]
16. A 10-Gene Yin Yang Expression Ratio Signature for Stage IA and IB Non-Small Cell Lung Cancer.
Xu W; Jia G; Davie JR; Murphy L; Kratzke R; Banerji S
J Thorac Oncol; 2016 Dec; 11(12):2150-2160. PubMed ID: 27498386
[TBL] [Abstract][Full Text] [Related]
17. Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancer.
Huang YC; Shen SM; Liu CY; Pavlidis S; Wang CL; Ko HW; Chung FT; Lin TY; Feng PH; Lee KY; Guo YK; Yang CT; Kuo CS
Thorac Cancer; 2018 Dec; 9(12):1648-1655. PubMed ID: 30259696
[TBL] [Abstract][Full Text] [Related]
18. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
Jiao XD; Qin BD; You P; Cai J; Zang YS
Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
